HelloBetter
HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.
Growth Trajectory
HelloBetter demonstrates growth potential by serving over 120,000 participants and partnering with over 15,000 doctors and psychotherapists; they can further expand within the German healthcare system through DiGA certification and by continuously developing new science-based online therapy courses. Their focus on research, development, and scientific validation will likely drive future innovation and market reach, expanding their product offerings and partnerships with healthcare providers and insurance companies.
Technical Challenges
Tech Stack
Team Size
Key Risks
Opportunities
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats